Carnosine Did Not Affect Vascular and Metabolic Outcomes in Patients with Prediabetes and Type 2 Diabetes: A 14-Week Randomized Controlled Trial.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: MDPI Publishing Country of Publication: Switzerland NLM ID: 101521595 Publication Model: Electronic Cited Medium: Internet ISSN: 2072-6643 (Electronic) Linking ISSN: 20726643 NLM ISO Abbreviation: Nutrients Subsets: MEDLINE
    • Publication Information:
      Original Publication: Basel, Switzerland : MDPI Publishing
    • Subject Terms:
      Diabetes Mellitus, Type 2*/drug therapy ; Prediabetic State*/drug therapy ; Carnosine* ; Vascular Stiffness*; Adult ; Humans ; Pulse Wave Analysis ; Dietary Supplements ; Double-Blind Method ; Lipids
    • Abstract:
      Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of morbidity and mortality in patients with prediabetes and type 2 diabetes mellitus (T2DM). Carnosine has been suggested as a potential approach to reduce ASCVD risk factors. However, there is a paucity of human data. Hence, we performed a 14-week double-blind randomized placebo-controlled trial to determine whether carnosine compared with placebo improves vascular and metabolic outcomes in individuals with prediabetes and T2DM. In total, 49 patients with prediabetes and T2DM with good glycemic control were randomly assigned either to receive 2 g/day carnosine or matching placebo. We evaluated endothelial dysfunction, arterial stiffness, lipid parameters, blood pressure, heart rate, hepatic and renal outcomes before and after the intervention. Carnosine supplementation had no effect on heart rate, peripheral and central blood pressure, endothelial function (logarithm of reactive hyperemia (LnRHI)), arterial stiffness (carotid femoral pulse wave velocity (CF PWV)), lipid parameters, liver fibroscan indicators, liver transient elastography, liver function tests, and renal outcomes compared to placebo. In conclusion, carnosine supplementation did not improve cardiovascular and cardiometabolic risk factors in adults with prediabetes and T2DM with good glycemic control. Therefore, it is improbable that carnosine supplementation would be a viable approach to mitigating the ASCVD risk in these populations. The trial was registered at clinicaltrials.gov (NCT02917928).
    • References:
      Diabetes. 2005 Aug;54(8):2320-7. (PMID: 16046297)
      Amino Acids. 2012 Jun;42(6):2411-6. (PMID: 21833769)
      Nutrition. 2000 Mar;16(3):168-72. (PMID: 10705070)
      Curr Vasc Pharmacol. 2012 Jan;10(1):19-32. (PMID: 22112354)
      J Cell Mol Med. 2011 Jun;15(6):1339-54. (PMID: 20518851)
      Antioxidants (Basel). 2021 Jun 28;10(7):. (PMID: 34203479)
      Sci Rep. 2017 Dec 12;7(1):17458. (PMID: 29234057)
      Nutrients. 2015 Jan 29;7(2):887-904. (PMID: 25642970)
      Gastroenterol Hepatol (N Y). 2012 Sep;8(9):605-7. (PMID: 23483859)
      Amino Acids. 2016 May;48(5):1131-49. (PMID: 26984320)
      Eur J Pharmacol. 1984 Mar 16;99(1):79-84. (PMID: 6723792)
      Nutr Metab Cardiovasc Dis. 2022 Oct;32(10):2289-2296. (PMID: 35973888)
      Arterioscler Thromb Vasc Biol. 2013 Jun;33(6):1162-70. (PMID: 23559625)
      Arch Gerontol Geriatr. 2014 Sep-Oct;59(2):485-90. (PMID: 24880197)
      Atherosclerosis. 2014 Feb;232(2):403-9. (PMID: 24468155)
      BMJ Open Diabetes Res Care. 2020 Apr;8(1):. (PMID: 32332069)
      Circ Res. 2020 Dec 4;127(12):1499-1501. (PMID: 33270547)
      Cardiovasc Diabetol. 2016 Mar 24;15:51. (PMID: 27013319)
      J Hypertens. 2012 Dec;30(12):2395-402. (PMID: 23041752)
      Eur J Pharmacol. 2003 Aug 8;474(2-3):261-7. (PMID: 12921872)
      Perspect Clin Res. 2016 Jul-Sep;7(3):144-6. (PMID: 27453832)
      Nutrients. 2022 Jan 04;14(1):. (PMID: 35011089)
      Curr Med Chem. 2020;27(11):1744-1763. (PMID: 31296153)
      Cell Physiol Biochem. 2011;28(2):279-88. (PMID: 21865735)
      Med Sci Sports Exerc. 2003 Aug;35(8):1381-95. (PMID: 12900694)
      Pediatr Diabetes. 2018 May;19(3):470-477. (PMID: 28744992)
      FEBS Lett. 2007 Mar 6;581(5):1067-70. (PMID: 17316626)
      Diabetologia. 2015 Apr;58(4):845-53. (PMID: 25471794)
      Nutrition. 2015 Jan;31(1):72-8. (PMID: 25287762)
      Amino Acids. 2012 Jul;43(1):97-109. (PMID: 22367578)
      BMC Nephrol. 2021 Jun 26;22(1):236. (PMID: 34174842)
      Auton Neurosci. 2002 May 31;97(2):99-102. (PMID: 12132650)
      Schizophr Res. 2012 Dec;142(1-3):145-52. (PMID: 23099060)
      Free Radic Res. 2021 Apr;55(4):321-330. (PMID: 33302741)
      Med Sci Monit. 2014 Mar 11;20:399-405. (PMID: 24614724)
      Sci Rep. 2017 Mar 10;7:44492. (PMID: 28281693)
      J Am Heart Assoc. 2019 Oct 15;8(20):e012509. (PMID: 31583936)
      Eur J Pharmacol. 2011 Feb 25;653(1-3):82-8. (PMID: 21167151)
      Nutrients. 2019 May 28;11(6):. (PMID: 31141890)
      BMJ. 2013 Jan 08;346:e7586. (PMID: 23303884)
      Med Sci Monit. 2018 Jan 15;24:305-316. (PMID: 29334583)
      Br J Pharmacol. 2012 Jun;166(4):1344-56. (PMID: 22229552)
      Behav Res Methods. 2007 May;39(2):175-91. (PMID: 17695343)
      Chem Res Toxicol. 2020 Jul 20;33(7):1561-1578. (PMID: 32202758)
      Life Sci. 2019 Nov 15;237:116905. (PMID: 31610198)
      Curr Biol. 2017 Jul 24;27(14):R713-R715. (PMID: 28743020)
      J Diabetes Res. 2019 Feb 17;2019:2161085. (PMID: 30911551)
      Complement Ther Med. 2020 Jan;48:102241. (PMID: 31987255)
      Diabet Med. 1998 Jul;15(7):539-53. (PMID: 9686693)
      Clin Res Hepatol Gastroenterol. 2017 Sep;41(4):424-434. (PMID: 28283328)
      J Hypertens. 2011 Apr;29(4):749-57. (PMID: 21192271)
      Physiol Rev. 2013 Oct;93(4):1803-45. (PMID: 24137022)
      Exp Clin Endocrinol Diabetes. 2017 May;125(5):282-289. (PMID: 28407658)
      Scand J Clin Lab Invest. 2019 Feb - Apr;79(1-2):108-116. (PMID: 30761923)
      Nutr Res Pract. 2011 Oct;5(5):421-8. (PMID: 22125679)
      Cardiovasc Diabetol. 2022 May 14;21(1):74. (PMID: 35568946)
      Obesity (Silver Spring). 2016 May;24(5):1027-34. (PMID: 27040154)
      Biomedicines. 2020 Jun 29;8(7):. (PMID: 32610588)
      Am J Kidney Dis. 2007 Oct;50(4):622-30. (PMID: 17900462)
      Adv Nutr. 2022 Oct 2;13(5):1914-1929. (PMID: 35689661)
      Circ Res. 2016 Feb 19;118(4):620-36. (PMID: 26892962)
      Am J Physiol Renal Physiol. 2022 Jul 1;323(1):F69-F80. (PMID: 35635322)
      Br J Pharmacol. 2017 Jun;174(12):1591-1619. (PMID: 27187006)
    • Grant Information:
      None Royal Australasian College of Physicians
    • Contributed Indexing:
      Keywords: Carnosine; RCT; cardiovascular risk; diabetes; insulin resistance; metabolic health; randomized trial
    • Molecular Sequence:
      ClinicalTrials.gov NCT02917928
    • Accession Number:
      8HO6PVN24W (Carnosine)
      0 (Lipids)
    • Publication Date:
      Date Created: 20231125 Date Completed: 20231127 Latest Revision: 20231127
    • Publication Date:
      20231128
    • Accession Number:
      PMC10674211
    • Accession Number:
      10.3390/nu15224835
    • Accession Number:
      38004228